Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
VectorY logo — VectorY combines the therapeutic potential of antibodies and...

VectorY

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions.

Founded 2020 The Netherlands The Netherlands 109 employees Series A Total: $160.00M Biotechnology

General Information

Company Name VectorY
Founded Year 2020
Location The Netherlands The Netherlands +1
Founders / Decision Makers
Team member
Employees 109
Industries Biotechnology
Funding Stage Series A
Social

Get notified when VectorY moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

VectorY has recently strengthened its scientific foundation through a collaboration with Wageningen University & Research, culminating in a new publication in Trends in Biotechnology. Concurrently, the company demonstrated its commitment to the patient community by attending the Wings Over Wall Street fundraising event for ALS. These developments collectively underscore VectorY's progress in scientific validation and its strategic engagement with both research and patient advocacy within its specialized therapeutic areas.

Signal Types
Partnership R&D Advancement Community Engagement
Strategic Labels
Research Collaboration Scientific Validation Patient Advocacy
Next Move: Clinical Trials
·
Impact: 7/10
·
Ideal For: Biotech VCs - Growth Stage, Strategic Pharma Partners

About VectorY

VectorY is a promising player in the Biotechnology industry, leveraging the therapeutic potential of antibodies and gene therapy to address large disease areas with high unmet medical needs. Founded in August 2020 and based in the Amsterdam Science Park, this fully integrated gene therapy company is making strides in developing innovative treatments, particularly focusing on CNS and muscle disorders.

The company distinguishes itself with its proprietary AAV-based vectorized antibody and gene therapy platform, which is geared towards enhancing therapeutic innovation. Their headway is reinforced by their own manufacturing facilities, capable of delivering suspension-based AAV viral vector manufacturing up to 2000L, ensuring scalability from clinical to commercial supply.

VectorY secured a substantial €129.00M Series A investment on 01 November 2023, backed by notable investors including Insight Partners, BioGeneration Ventures, Forbion, ALS Investment Fund, EQT Life Sciences, and MRL Ventures.

Taxonomy: gene therapy, antibody therapy, vectorized antibodies, CNS disorders, somatic disorders, muscle diseases, AAV-based vector technology, therapeutic development, biopharmaceutical manufacturing, suspension-based viral vector manufacturing, GMP facility, innovative therapeutics, R&D

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 6
Investor Investor Investor Investor
•••• •••• 		01 Nov 2023
Seed •••••• 3
Investor Investor Investor
01 Jun 2021

Latest News

View All
Capital meets care: 10 venture capital firms transforming healthcare across Europe — Eu-startups
Capital meets care: 10 venture capital firms transforming healthcare across Europe
Eu-startups Sep 18, 2025

VectorY Alternatives & Competitors

VectorY vs
Genezen
Genezen United States

Bringing Therapies to Life

Growth
272 employees
Compare VectorY vs Genezen
VectorY vs
StrideBio, Inc
StrideBio, Inc United States

The next evolution in gene therapy

Acquired
4 employees
Biotechnology, Health Care
Compare VectorY vs StrideBio, Inc
VectorY vs
CoJourney
CoJourney United States

Reimagining Cell and Gene Therapy CDMO Services High Purity | High Yield | Rapid Turnaround | Reduc...

Series A
7 employees
Biopharma, Health Care
Compare VectorY vs CoJourney

FAQ About VectorY

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions.
VectorY was founded in 2020.
VectorY is headquartered in The Netherlands.
VectorY operates in the following industries: Biotechnology.
VectorY has approximately 109 employees.
VectorY has completed 2 funding rounds, raising a total of $160.00M. The latest funding stage is Series A.
Top alternatives and competitors to VectorY include Genezen, StrideBio, Inc, CoJourney, Exegenesis Bio, MSN Laboratories. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VectorY and Genezen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors VectorY and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy